phathom pharmaceuticals, inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. the company has the rights in the united states, europe, and canada to vonoprazan, a potassium-competitive acid blocker (p-cab) that blocks acid secretion in the stomach. it is also developing vonoprazan, which is in phase iii clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of helicobacter pylori infection. the company was incorporated in 2018 and is based in buffalo grove, illinois.
Company profile
Ticker
PHAT
Exchange
Website
CEO
Terrie Curran
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
824151574
PHAT stock data
Latest filings (excl ownership)
DEFA14A
Additional proxy soliciting materials
12 Apr 24
DEF 14A
Definitive proxy
12 Apr 24
ARS
2023 FY
Annual report to shareholders
12 Apr 24
10-K
2023 FY
Annual report
7 Mar 24
8-K
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
7 Mar 24
8-K
Other Events
13 Feb 24
8-K
Amendments to Articles of Incorporation or Bylaws
15 Dec 23
8-K
Entry into a Material Definitive Agreement
14 Dec 23
8-K
Other Events
6 Dec 23
8-K
Other Events
28 Nov 23
Transcripts
Latest ownership filings
4
Molly Henderson
10 Apr 24
SC 13D/A
TAKEDA PHARMACEUTICAL CO LTD
10 Apr 24
SC 13D/A
TAKEDA PHARMACEUTICAL CO LTD
1 Apr 24
4
Terrie Curran
26 Mar 24
SC 13G/A
Carlyle Group Inc.
12 Feb 24
SC 13G/A
Invesco Ltd.
9 Feb 24
3
Initial statement of insider ownership
26 Jan 24
SC 13G/A
Medicxi Growth I LP
26 Jan 24
4
Change in insider ownership
25 Jan 24
SC 13D/A
TAKEDA PHARMACEUTICAL CO LTD
25 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 216.54 mm | 216.54 mm | 216.54 mm | 216.54 mm | 216.54 mm | 216.54 mm |
Cash burn (monthly) | 10.95 mm | (no burn) | 11.89 mm | 12.01 mm | 10.64 mm | 11.24 mm |
Cash used (since last report) | 74.99 mm | n/a | 81.43 mm | 82.25 mm | 72.87 mm | 76.97 mm |
Cash remaining | 141.55 mm | n/a | 135.11 mm | 134.29 mm | 143.66 mm | 139.57 mm |
Runway (months of cash) | 12.9 | n/a | 11.4 | 11.2 | 13.5 | 12.4 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 115 |
Opened positions | 15 |
Closed positions | 7 |
Increased positions | 48 |
Reduced positions | 24 |
13F shares | Current |
---|---|
Total value | 445.52 bn |
Total shares | 65.36 mm |
Total puts | 29.20 k |
Total calls | 95.10 k |
Total put/call ratio | 0.3 |
Largest owners | Shares | Value |
---|---|---|
Frazier Life Sciences Management | 10.11 mm | $104.83 bn |
TAK Takeda Pharmaceutical | 7.46 mm | $169.55 mm |
Frazier Life Sciences IX | 5.83 mm | $58.39 mm |
Frazier Life Sciences Public Fund | 5.83 mm | $68.24 mm |
Medicxi Ventures Management | 3.76 mm | $39.00 bn |
CG Carlyle Group Inc | 3.50 mm | $36.19 bn |
IVZ Invesco | 3.42 mm | $35.45 bn |
Medicxi Growth I | 2.48 mm | $0.00 |
BLK Blackrock | 2.44 mm | $25.28 bn |
Vanguard | 1.92 mm | $19.94 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
8 Apr 24 | Henderson Molly | Common Stoock | Sell | Dispose S | No | No | 11.1 | 3,435 | 38.13 k | 95,263 |
22 Mar 24 | Curran Terrie | Common Stock | Sell | Dispose S | No | No | 9.11 | 16,851 | 153.51 k | 410,784 |
24 Jan 24 | Takeda Pharmaceutical | Common Stock | Sell | Dispose S | No | No | 8.1 | 3,703,703 | 30.00 mm | 3,755,583 |
18 Jan 24 | Curran Terrie | Stock Option Common Stock | Grant | Acquire A | No | No | 7.6 | 475,000 | 3.61 mm | 475,000 |
News
Needham Reiterates Buy on Phathom Pharmaceuticals, Maintains $26 Price Target
19 Apr 24
Needham Reiterates Buy on Phathom Pharmaceuticals, Maintains $26 Price Target
12 Apr 24
Needham Reiterates Buy on Phathom Pharmaceuticals, Maintains $26 Price Target
11 Apr 24
Needham Reiterates Buy on Phathom Pharmaceuticals, Maintains $26 Price Target
5 Apr 24
Needham Reiterates Buy on Phathom Pharmaceuticals, Maintains $26 Price Target
1 Apr 24
Press releases
SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCT
22 Apr 24
Navigating Interest Rate Speculations and M&A Trends with a Spotlight on Actinium Pharmaceuticals (ATNM)
18 Apr 24
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
7 Mar 24
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024
29 Feb 24
Thinking about buying stock in Meta Platforms, Ocular Therapeutix, Phathom Pharmaceuticals, Revelation Biosciences, or Sunworks?
12 Feb 24